Camp4 Therapeutics Corp CAMP
Camp4 Therapeutics Corp (Nasdaq: CAMP) is a CNS/neurology/psychiatry drug developer. Its lead program, CMP-002, is in Phase 1 for SYNGAP1-related disorder (developmental and epileptic encephalopathy). Its next catalyst on record is CMP-002 ASCEND Phase 1/2 trial: First patient dosed (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CMP-002 ASCEND Phase 1/2 trial — First patient dosed (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CMP-002 | SYNGAP1-related disorder | oligonucleotide-other | Phase 1 |
| SHANK3 program | Phelan-McDermid syndrome | oligonucleotide-other | Pre-clinical |
| Two additional haploinsufficient CNS programs | CNS diseases (not specified) | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Nov 5, 2026started CAMP4 initiated the ASCEND Phase 1/2 clinical trial of CMP-002 in SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026.
The Company has initiated the ASCEND Phase 1/2 clinical trial of CMP-002 and remains on track to dose the first patient by year-end 2026.
Filing - submitted CAMP4 received authorization from multiple EU regulators and ethics committees in October 2026 to include EU sites in the ASCEND Phase 1/2 clinical trial.
received authorization from multiple EU regulators and ethics committees in October 2026 to include UK and EU sites in the global ASCEND Phase 1/2 clinical trial of CMP-002.
Filing - submitted CAMP4 received authorization from the UK MHRA in September 2026 to include UK sites in the ASCEND Phase 1/2 clinical trial.
Received authorization from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) in September 2026.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.